Skip To Main Content
Yunchun Long on Muck Rack

Yunchun Long

As seen in: BMJ Open
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yunchun

Contact Yunchun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China

|
By Yunchun Long, Hao Wang, Xianhai Xie, Junlin Li
| BMJ Open Verified
Discussion The combination of PD-L1 inhibitors with chemotherapy has been shown to significantly improve survival in patients with ES-SCLC, as demonstrated by international IMpower133 and CASPIAN studies.
Open in Who Shared View Duplicates (2) Issue with article?

Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China

|
By Fang Chen, Yunchun Long, Jiayong Yang, Kailong Zhong
| BMJ Open Verified
Discussion The first-line systemic treatment options for advanced or metastatic OSCC are limited. Palliative chemotherapy not only has limited survival benefits, but also has serious AEs. Fortunately, with the progress of medical research, immunotherapy has achieved more survival benefits.
Open in Who Shared Issue with article?

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China

|
By Yuan Xu, Li Liao, Yujie Zhou, Yunchun Long
| BMJ Open Verified
Discussion In recent years, the emergence of immunotherapy drugs has broken the dilemma of SCLC treatment.10–12 Clinical trials such as IMpower133 and CASPIAN have confirmed the efficacy and safety of programmed cell death-ligand 1 (PD-L1) inhibitors in the first-line treatment of SCLC.14 15 Therefore, FDA and NMPA have approved PD-L1 inhibitors, such as atezolizumab or durvalumab coupled with chemotherapy for the first-line treatment of ES-SCLC.13 It is also recommended by NCCN and CSCO...
Open in Who Shared Issue with article?
See all 3 articles